ArticleFrontiers in nutrition2025
African walnut (
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: African walnut ( Objective: The present study investigated the effect of AWO on glucose uptake and its effect on glucose metabolism, purinergic and antioxidant activities and surface morphology in isolated rats' erythrocytes Methods: Isolated erythrocytes were incubated with AWO (30-240 μg/mL) and glucose (11.1 mM) for 2 h at 37°C. Negative control consisted of erythrocytes incubated with glucose only, while normal control consisted of erythrocytes not incubated with AWO and/or glucose. Metformin served as the standard hypoglycemic drug. Results and conclusion: Incubation with AWO led to significant increase in erythrocyte glucose uptake, with concomitant suppression in superoxide dismutase, adenosine triphosphatase, ecto-nucleoside triphosphate diphosphohydrolase, glucose 6-phosphatse and fructose-1,6-bisphosphatase activities and iron level, while concomitantly enhancing glutathione and magnesium levels. Furthermore, the surface morphology of erythrocytes was improved following incubation with AWO. Molecular docking analysis revealed strong molecular interactions between AWO's phytoconstituents (linolenic acid and linoleic acid) and hemoglobin. Molecular dynamics simulation further revealed strong protein-ligand relationships between hemoglobin the oil's constituents as revealed by root mean square deviation, root mean square fluctuation, solvent accessible surface area, and radius of gyration values, with hydrogen, hydrophobic, ionic bonds and water bridges contributing to the stability of the protein-ligand complex. These results suggest the ability of AWO to improve erythrocyte glucose metabolism and morphology, mitigate oxidative stress, and may be of translational relevance in managing erythrocytes' dysfunction in metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.